Antibody brings proteins together to tame autoimmune hepatitis
BiTS, an antibody co-developed by researchers at New York University (NYU) to tame overactive immune T-cells, reduced inflammation and liver damage in a study that…
BiTS, an antibody co-developed by researchers at New York University (NYU) to tame overactive immune T-cells, reduced inflammation and liver damage in a study that…
An imbalance in the blood between long-chain and very long-chain ceramides — fatty molecules that help fine-tune the body’s inflammatory response — may help indicate…
About 40 in every 100,000 U.S. adults have primary biliary cholangitis (PBC), with its frequency, when adjusted to population size, being highest in some…
Researchers have developed a database of all ABCB11 mutations known to cause progressive familial intrahepatic cholestasis type 2 (PFIC2) and a new mouse model…
A targeted treatment called transarterial chemoembolization (TACE) successfully helped control hepatocellular carcinoma (HCC), the most common type of liver cancer, in a young woman with…
AusperBio raised $50 million to advance the development of chronic hepatitis B treatment AHB-137. The company said the funding will help it launch Phase…
The U.S. Food and Drug Administration (FDA) has accepted for review GSK’s application seeking the approval of its oral treatment linerixibat for intense itching, or…
Hepatitis Awareness Month is held every May to raise awareness about viral hepatitis, an inflammation of the liver caused by a virus, and help…
Exposure to high levels of fine particulate matter, or PM2.5, the most commonly studied air pollutant, and reduced time in the sunlight in the three…
A study of three children with progressive familial intrahepatic cholestasis type 3 (PFIC3) in China revealed that different disease-causing mutations in the ABCB4 gene,…